Skip to main content

Table 3 In-dwell characteristics and adverse events of PORT-inserted patients, stratified by solid tumours versus the control group

From: Impact of the COVID-19 pandemic on subcutaneous venous port-related complications in patients with cancer: a retrospective case–control study

Complications, haematological cancer — solid tumours

2020 solid tumours

Control group

HR

95% CI

p-value

n = 201

n = 168

Total catheter days

29,071

37,469

CD per patient, median (IQR)

175 (69)

217 (179)

< 0.001

Mortality, n (%)

36 (17.9)

34 (20.2)

1.5

0.9–2.6

0.121

DVT, n (%)

2 (1.0)

1 (0.6)

2.0

0.2–21.9

0.578

DVT/1000 CD

0.07

0.03

Days to DVT, median (IQR)

85 (−)

All catheter infections, n (%)

9 (4.5)

16 (9.5)

0.6

0.3–1.4

0.211

Infection/1000 CD

0.31

0.43

Local infection, n (%)

9 (4.5)

15 (8.9)

CRI, n (%)

3 (1.5)

CRBSI, n (%)

2 (1.0)

2 (1.2)

1.8

0.2–20.1

0.623

CRBSI/1000 CD

0.07

0.05

Days to infection median (IQR)

56 (85)

46 (96)

0.428

Haematoma, n (%)

10 (5.0)

2 (1.2)

0.043

Antibiotics, n (%)

22 (10.1)

2 (1.2)

  

< 0.001

Mechanical, n (%)

6 (3.0)

7 (4.2)

1.0

0.3–3.0

0.945

Mechanical/1000 CD

0.21

0.19

Days to mechanical event median (IQR)

16 (57)

122 (107)

0.015

Occlusion, n (%)

18 (9.0)

1 (0.6)

16.2

2.2–121.1

0.007

Occlusion/1000 CD

0.62

0.03

  

Days to occlusion median (IQR)

17 (43)

– (−)

All grade adverse events, n (%)

37 (18.4)

25 (14.9)

1.7

1.0–2.9

0.068

All grade adverse events/1000 CD

1.27

0.67

Days to all grade adverse events median (IQR)

22 (63)

60 (114)

0.001

  1. HR hazard ratio, CI confidence interval, CD catheter days, IQR interquartile range, DVT deep venous thrombosis, CRI catheter-related infection, CRBSI catheter-related bloodstream infection